Acrivon Therapeutics (ACRV) Q1 2026 earnings summary

Executive summary

• Focused on precision oncology, leveraging the AP3 platform for drug discovery and patient selection, with lead programs ACR-368 (CHK1/2 inhibitor) in Phase 2b and ACR-2316 (WEE1/PKMYT1 inhibitor) in Phase 1/2 trials, advancing toward key 2026 clinical milestones.

• Interim Phase 2b data for ACR-368 in endometrial cancer showed a 39% ORR in Arm 1 and 52% in pooled serous EC subjects with ≤2 prior lines of therapy, with rapid enrollment and strong clinical activity observed.

• All clinical and preclinical programs remain unpartnered, with no revenue generated to date.

• Cash position of $97.7 million as of March 31, 2026, plus $7.3 million from equity financing, expected to fund operations into Q3 2027.

Financial highlights

• Net loss was $19.0 million for Q1 2026, compared to $19.7 million for Q1 2025.

• Research and development expenses were $15.2 million, nearly flat year-over-year.

• General and administrative expenses decreased to $4.7 million from $6.2 million year-over-year, mainly due to lower stock-based compensation and employee-related costs.

• Cash, cash equivalents, and investments totaled $97.7 million as of March 31, 2026.

• Net cash used in operating activities was $20.5 million for Q1 2026.

Outlook and guidance

• Existing cash and recent ATM proceeds are expected to fund operations into Q3 2027, supporting multiple anticipated clinical milestones.

• Prespecified interim analysis for both serous EC arms of ACR-368 Phase 2b planned for H2 2026.

• Readiness for Phase 3 confirmatory trial for ACR-368 with PD-1 therapy targeted by mid-2026.

• Additional ACR-2316 clinical data and dose expansion expected in 2026.

• IND filing for CDK11 inhibitor candidate planned for H1 2027.